Moderna

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Moderna 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. 

CEO
Stéphane Bancel
CEOStéphane Bancel
Employees
5,800
Employees5,800
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2010
Founded2010
Employees
5,800
Employees5,800

MRNA Key Statistics

Market cap
12.19B
Market cap12.19B
Price-Earnings ratio
-3.87
Price-Earnings ratio-3.87
Dividend yield
Dividend yield
Average volume
11.20M
Average volume11.20M
High today
$32.72
High today$32.72
Low today
$31.00
Low today$31.00
Open price
$32.50
Open price$32.50
Volume
6.32M
Volume6.32M
52 Week high
$48.92
52 Week high$48.92
52 Week low
$22.28
52 Week low$22.28

Stock Snapshot

The current Moderna(MRNA) stock price is $31.13, with a market capitalization of 12.19B. The stock trades at a price-to-earnings (P/E) ratio of -3.87.

During the trading session on 2025-12-29, Moderna(MRNA) shares reached a daily high of $32.72 and a low of $31.00. At a current price of $31.13, the stock is +0.4% higher than the low and still -4.9% under the high.

Trading activity shows a volume of 6.32M, compared to an average daily volume of 11.2M.

The stock's 52-week range extends from a low of $22.28 to a high of $48.92.

The stock's 52-week range extends from a low of $22.28 to a high of $48.92.

MRNA News

Nasdaq 2d
Forget Moderna Stock, This is a Much Better Buy

Key Points Moderna stock soared in the early stages of the pandemic, then struggled -- but in recent times, it’s been on the rise. This other biotech has prov...

Forget Moderna Stock, This is a Much Better Buy
Simply Wall St 3d
Could CEPI’s Bird Flu Backing Mark a Turning Point in Moderna’s mRNA Diversification Strategy?

In recent weeks, Moderna secured up to US$54.3 million in CEPI funding to advance late-stage development of its bird flu vaccine candidate mRNA-1018 and receive...

Could CEPI’s Bird Flu Backing Mark a Turning Point in Moderna’s mRNA Diversification Strategy?

Analyst ratings

62%

of 26 ratings
Buy
19.2%
Hold
61.5%
Sell
19.2%

People also own

Based on the portfolios of people who own MRNA. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.